Drug Profile

Suratadenoturev - Oncolys Biopharma

Alternative Names: OBP-301; Telomelysin; Telomerase-specific Type 5 Adenovirus OBP-301 - Oncolys Biopharma

Latest Information Update: 03 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Oncolys Biopharma
Developer Chugai Pharmaceutical; Cornell University; Medigen Biotechnology Corporation; Okayama University; Oncolys BioPharma
Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses; Viral proteins
Mechanism of Action Cell death stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Oesophageal cancer
New Molecular Entity No
Available For Licensing Yes

Phase II Adenocarcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Oesophageal cancer
Phase I/II Liver cancer; Non-small cell lung cancer
No development reported Adenoid cystic carcinoma; Breast cancer; Mesothelioma; Neuroblastoma; Osteosarcoma; Skin cancer; Soft tissue sarcoma; Solid tumours

27 Jan 2025 Adverse events data from a phase I trial in Oesophageal cancer and Gastric cancer presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI-2025)
28 Nov 2024 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy) in Unknown (Intratumoural, Injection)
25 Apr 2024 Oncolys Biopharma initiates a phase II trial in Adenocarcinoma (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT06340711)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com